# Family Office Of America, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Family Office Of America, Inc.). ## Overview Family Office of America, Inc. is a U.S.-based medical device company that appears to be in an early commercial stage, with filings showing capital raising and equity-based compensation activity rather than established operating revenue. The company’s disclosed history includes a subsidiary relationship with mPathix Health, Inc. and a license agreement tied to Life Care Medical Devices Limited, suggesting a product-development and commercialization model in surgical and medical instruments. ## Products & services • Surgical and medical instruments and apparatus • Licensed medical device technology through mPathix Health • Product development and commercialization of medical devices • Equity-funded corporate and consulting services support - **Surgical & medical instruments** (70%) — Core medical device products and apparatus intended for clinical or procedural use. - **Licensed device technology** (20%) — Technology rights and know-how obtained through licensing arrangements for medical products. - **Development-stage services** (10%) — Internal development, regulatory preparation, and commercialization support around device launch. - Surgical and medical instruments and apparatus - Licensed medical device technology through mPathix Health - Product development and commercialization of medical devices - Equity-funded corporate and consulting services support ## Customers The company’s likely customers are healthcare providers, distributors, and other commercial partners that buy or license medical device products and related technology. Because the filings emphasize financing, warrants, and a license agreement, the business appears oriented toward building a product platform before broad market penetration. Demand would depend on clinical adoption, regulatory clearance, and the ability to convert development assets into sellable medical products. - **Healthcare providers** (primary) — Hospitals, clinics, and procedural centers that would purchase or use medical devices in care delivery. - **Medical distributors** (secondary) — Channel partners that could buy devices in bulk and resell into healthcare markets. - **Licensing/commercial partners** (secondary) — Partners that may license technology or support product commercialization and market access. - **Accredited investors** (primary) — Investors providing capital through private placements to fund operations and development. - Hospitals and clinics that would use surgical/medical devices - Medical distributors seeking device inventory for resale - Licensing or commercialization partners in healthcare - Accredited investors funding the company’s development stage ## Geography The company is headquartered in the United States, and the available filings do not disclose meaningful country-level revenue or operating geography. Based on the disclosed license agreement and SEC reporting, the business is primarily U.S.-centric at this stage, with any future expansion likely tied to medical device commercialization and distribution. Geographic exposure is therefore more about regulatory jurisdiction and market access than current revenue diversification. - United States is the disclosed home market and reporting base - No country-level revenue disclosure was provided in the excerpts - Medical device commercialization would be shaped by U.S. regulation - Future international expansion is not yet evidenced in the filings ## Strategy The company’s near-term strategy appears focused on financing the business, advancing medical device-related assets, and building a path to commercialization. The disclosed private placement and consulting warrants suggest management is prioritizing capital formation and execution capacity before scale revenue. The license agreement with Life Care Medical Devices Limited indicates a strategy of using external technology rights rather than relying solely on in-house invention. - **Complete financing and preserve working capital** (short-term) — The company is still funding development and corporate activity through private placements. - **Advance licensed medical device assets** (medium-term) — Licensed technology can shorten time to market versus building products from scratch. - **Establish a commercial platform** (medium-term) — Sustainable value depends on converting development-stage assets into marketable products. - Raise equity capital to fund operations and development - Use licensing to access medical device technology faster - Build commercialization capability around surgical/medical products - Compensate key personnel and consultants with warrants ## Risks The company faces classic development-stage medical device risks: limited operating history, dependence on external financing, and uncertainty around product commercialization. Because the business relies on licensed technology and equity issuance, execution risk, dilution risk, and valuation risk are likely more important than near-term operating margin pressure. Regulatory, clinical adoption, and intellectual property risks are also material in surgical and medical instruments. - **Financing dependence and dilution** [high] — The company raised capital through a private placement and issued warrants, indicating reliance on external funding. - **Commercialization failure** [high] — Medical device businesses must convert development assets into clinically adopted products, which is uncertain. - **Regulatory and compliance risk** [high] — Surgical and medical instruments are subject to healthcare regulation, quality systems, and market clearance requirements. - **Third-party licensing dependence** [medium] — The company references a license agreement, so access to technology may depend on contractual terms and counterparties. - Dependence on equity financing can dilute existing shareholders - Commercialization risk if licensed products do not gain adoption - Regulatory approval and compliance risk in medical devices - IP/licensing dependence on third-party technology rights - Limited operating history increases execution and going-concern risk ## Accounting The most important accounting issue in the excerpts is equity issuance and warrant valuation, which can materially affect share-based compensation expense and additional paid-in capital. Because the company appears early stage, investors should also watch whether any future revenue is recognized from product sales, licensing, or services and how management applies judgment around fair value estimates. If the business remains development-stage, going-concern disclosures, warrant remeasurement, and consulting compensation accounting may be especially important. - **Warrant valuation and remeasurement** — Can create non-cash expense and earnings volatility - **Equity issuance accounting** — Changes shareholders' equity and per-share metrics - **Share-based consulting compensation** — Affects operating expenses and APIC - Private placement share issuance affects equity and dilution - Warrants are valued using a binomial model and remeasured each period - Consulting compensation may be recognized as share-based expense - Future revenue recognition will depend on product or license terms - Development-stage disclosures may affect going-concern assessment --- *Last updated: 2026-04-28T20:06:02.601351+00:00*